文献速递类风湿关节炎

巴瑞替尼治疗中重度类风湿关节炎3年长期疗效研究

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究分析了两项52周III期研究(RA-BEGIN和RA-BEAM)及一项长期延伸研究(RA-BEYOND)共148周数据,评估巴瑞替尼4mg每日一次治疗活动性RA的长期疗效。结果显示,在初始接受巴瑞替尼治疗的患者中,第148周时DMARD初治患者SDAI低疾病活动度达61%、缓解达34%,MTX-IR患者分别达59%和24%,且耐受性良好。

要点

  • 巴瑞替尼4mg治疗中重度RA的疗效可持续长达3年
  • 第148周时DMARD初治患者SDAI缓解率最高34%,MTX-IR患者最高24%
  • MTX-IR患者因不良事件停药率10.7%,因疗效不足停药率3.6%

核心结论

  • 巴瑞替尼4mg每日一次在DMARD初治和MTX-IR的中重度RA患者中显示出长达3年的疗效且耐受性良好。

研究设计与样本

  • 分析两项已完成的52周III期研究(RA-BEGIN和RA-BEAM)及一项正在进行的长期延伸研究(RA-BEYOND)的数据,共148周。
  • RA-BEGIN中DMARD初治患者在第52周从MTX单药或巴瑞替尼4mg+MTX转为开放标签巴瑞替尼4mg单药;RA-BEAM中MTX-IR患者在第52周从阿达木单抗(+MTX)转为开放标签巴瑞替尼4mg(+MTX);安慰剂(+MTX)组在第24周转为巴瑞替尼4mg(+MTX)。

主要发现

  • 第148周时,初始接受巴瑞替尼治疗的DMARD初治患者中SDAI低疾病活动度(≤11)达成率高达61%,MTX-IR患者高达59%。
  • 第148周时,初始接受巴瑞替尼治疗的DMARD初治患者中SDAI临床缓解(≤3.3)达成率高达34%,MTX-IR患者高达24%。
  • 第148周时,初始接受巴瑞替尼治疗的DMARD初治患者中HAQ-DI≤0.5达成率高达48%,MTX-IR患者高达38%。
  • 148周内,MTX-IR患者中各治疗组因疗效不足停药的比例为3.6%,因不良事件停药的比例为10.7%;DMARD初治人群的停药率相似。

关键数值与推荐

  • 低疾病活动度定义:SDAI≤11;临床缓解定义:SDAI≤3.3;身体功能定义:HAQ-DI≤0.5。
  • 数据采用无应答者填补法进行分析。

临床怎么用

  • 巴瑞替尼4mg每日一次可作为DMARD初治或MTX-IR的中重度RA患者的长期治疗选择,疗效可持续3年且耐受性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the long-term efficacy of once-daily baricitinib 4 mg in patients with active RA who were either naïve to DMARDs or who had inadequate response (IR) to MTX. METHODS: Analyses of data from two completed 52-week, phase III studies, RA-BEGIN (DMARD-naïve) and RA-BEAM (MTX-IR), and one ongoing long-term extension (LTE) study (RA-BEYOND) were performed (148 total weeks). At week 52, DMARD-naïve patients treated with MTX monotherapy or baricitinib 4 mg+MTX in RA-BEGIN were switched to open-label baricitinib 4 mg monotherapy; MTX-IR patients treated with adalimumab (+MTX) in RA-BEAM were switched to open-label baricitinib 4 mg (+MTX) in the LTE. Patients who received placebo (+MTX) were switched to baricitinib 4 mg (+MTX) at week 24. Low disease activity (LDA) [Simple Disease Activity Index (SDAI) ≤11], clinical remission (SDAI ≤ 3.3), and physical functioning [Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ 0.5] were assessed. Data were assessed using a non-responder imputation. RESULTS: At week 148, SDAI LDA was achieved in up to 61% of DMARD-naïve patients and 59% of MTX-IR patients initially treated with baricitinib, and SDAI remission was achieved in up to 34% of DMARD-naïve patients and 24% of MTX-IR patients; HAQ-DI ≤ 0.5 was reached in up to 48% of DMARD-naïve patients and 38% of MTX-IR patients initially treated with baricitinib. Over 148 weeks, 3.6% and 10.7% of MTX-IR patients discontinued across treatment groups due to lack of efficacy or due to adverse events, respectively; discontinuation rates were similar in the DMARD-naïve population. CONCLUSION: Treatment with baricitinib 4 mg demonstrated efficacy for up to 3 years and was well tolerated.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Smolen JS, Xie L, Jia B, et al. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. Rheumatology (Oxford). 2021. PMID: 33200220. doi:10.1093/rheumatology/keaa576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。